Dimension Therapeutics has agreed to be acquired by RegenxBio, the gene therapy developer that originally helped form the company four years ago.
RegenxBio (NASDAQ: RGNX), based in Rockville, MD, will pay $3.41 per share in the all-stock deal valued at approximately $86 million. By comparison, Cambridge, MA-based Dimension (NASDAQ: DMTX) went public at $13 per share in 2015. Dimension’s closing stock price on Thursday was $1.20.
{iframe}http://www.xconomy.com/boston/2017/08/25/regenxbio-to-acquire-dimension-tx-in-combo-of-gene-therapy-companies/#{/iframe}